MA49478B1 - Nouveaux conjugués de montélukast et de peptides - Google Patents

Nouveaux conjugués de montélukast et de peptides

Info

Publication number
MA49478B1
MA49478B1 MA49478A MA49478A MA49478B1 MA 49478 B1 MA49478 B1 MA 49478B1 MA 49478 A MA49478 A MA 49478A MA 49478 A MA49478 A MA 49478A MA 49478 B1 MA49478 B1 MA 49478B1
Authority
MA
Morocco
Prior art keywords
peptide
montelukast
compound
containing compound
formula
Prior art date
Application number
MA49478A
Other languages
English (en)
Other versions
MA49478A (fr
Inventor
Ming Gu
Bengt Ingemar Samuelsson
Original Assignee
Enlitisa Shanghai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enlitisa Shanghai Pharmaceutical Co Ltd filed Critical Enlitisa Shanghai Pharmaceutical Co Ltd
Priority claimed from PCT/CN2019/105832 external-priority patent/WO2020052677A1/fr
Publication of MA49478A publication Critical patent/MA49478A/fr
Publication of MA49478B1 publication Critical patent/MA49478B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un composé contenant un peptide qui comprend un constituant peptidique, lequel est une séquence d'acides aminés constituée de 2 à 45 acides aminés, ledit constituant peptidique étant lié de manière covalente à un ou plusieurs composés de formule (i), r1 étant sélectionné dans le groupe constitué par -c(ch3)2oh, -coch3, -c(ch3)=ch2 et -c(ch3)2h, et n représentant 0, 1 ou 2, ainsi que des régioisomères, des stéréoisomères, et des sels pharmaceutiquement ou cosmétiquement acceptables dudit composé contenant un peptide. Le composé de formule i est de préférence le montélukast, le montélukast styrène ou le montélukast styrène hydrogéné. Le composé contenant un peptide est particulièrement utile dans le traitement de l'inflammation, y compris les plaies, les hémorroïdes, les brûlures, le psoriasis, l'acné, la dermatite atopique, la rhinite allergique, la conjonctivite allergique, la bronchopneumopathie chronique obstructive, les maladies inflammatoires intestinales (telles que la rectocolite hémorragique). Le composé contenant un peptide est également utilisable dans le traitement de la fibrose pulmonaire idiopathique.
MA49478A 2018-09-14 2019-09-14 Nouveaux conjugués de montélukast et de peptides MA49478B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018105703 2018-09-14
PCT/CN2019/105832 WO2020052677A1 (fr) 2018-09-14 2019-09-14 Nouveaux conjugués de montélukast et de peptides

Publications (2)

Publication Number Publication Date
MA49478A MA49478A (fr) 2020-03-19
MA49478B1 true MA49478B1 (fr) 2023-06-28

Family

ID=87758679

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49478A MA49478B1 (fr) 2018-09-14 2019-09-14 Nouveaux conjugués de montélukast et de peptides

Country Status (1)

Country Link
MA (1) MA49478B1 (fr)

Also Published As

Publication number Publication date
MA49478A (fr) 2020-03-19

Similar Documents

Publication Publication Date Title
Basso et al. Protective effect of long-term angiotensin II inhibition
AU2011316690B2 (en) Cyclosporin analogs
Verano-Braga et al. Structure–function studies of Tityus serrulatus Hypotensin-I (TsHpt-I): A new agonist of B2 kinin receptor
Meng et al. Injury of cell tight junctions and changes of actin level in acute lung injury caused by the perfluoroisobutylene exposure and the role of Myosin light chain kinase
AU2015296675B2 (en) Cyclic urea compounds as Granzyme B inhibitors
US20180000825A1 (en) Novel uses
MA49478B1 (fr) Nouveaux conjugués de montélukast et de peptides
TW201408702A (zh) 環孢素ａ類似物
CA3189653A1 (fr) Cyclotides en tant qu'agents immunosuppresseurs
CN107530330A (zh) 疼痛的治疗
CN102325768B (zh) 治疗疼痛和其他疾病的化合物和方法
MX2022003057A (es) Nuevos peptidos.
Wang et al. Hydrogen sulfide restores cardioprotective effects of remote ischemic preconditioning in aged rats via HIF-1α/Nrf2 signaling pathway
CN110845425A (zh) 一种酞嗪衍生物及其制备方法和应用
Sikiric The pharmacological properties of the novel peptide BPC 157 (PL-10)
JP4777344B2 (ja) 南米ガラガラヘビ（ｃｒｏｔａｌｕｓｄｕｒｉｓｓｕｓｔｅｒｒｉｆｉｃｕｓｓｎａｋｅｓ）毒液に由来する鎮痛ペプチドの類似化合物、これらの使用、組成物、調製と精製の方法
AU2005276117C1 (en) Peptide inhibitors for mediating stress responses
JP2008504234A6 (ja) 南米ガラガラヘビ（ｃｒｏｔａｌｕｓｄｕｒｉｓｓｕｓｔｅｒｒｉｆｉｃｕｓｓｎａｋｅｓ）毒液に由来する鎮痛ペプチドの類似化合物、これらの使用、組成物、調製と精製の方法
Nishanth et al. Three bioactive cyclic dipeptides from the Bacillus sp. N strain associated with entomopathogenic nematode
WO2015144977A1 (fr) Modulateurs de trpa1
MD3678705T2 (ro) Conjugați de montelukast și peptide
Zhang et al. Thymopentin improves the survival of septic mice by promoting the production of 15-deoxy-prostaglandin J2 and activating the PPARγ signaling pathway
EP2699545B1 (fr) Nouveaux derives amino-pyrroliniques, leur utilisation dans la prevention et/ou le traitement du syndrome metabolique
Teixeira et al. Sequence and structure‐activity relationship of a scorpion venom toxin with nitrergic activity in rabbit corpus cavernosum
JP2016523813A (ja) 医学的使用、特に酸化ストレスまたは炎症に関連する疾患の治療、および臓器の保存または洗浄のための、バレッチンおよびその誘導体